37 recruiting, 28 completed, 27 unknown, 15 terminated. 129 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 129 | Recruiting 37, Completed 28, Unknown 27, Terminated 15, Not yet recruiting 13, Active not recruiting 4, Withdrawn 4, Suspended 1 |
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia GT737 Injection - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Early Phase 1 | Not yet recruiting | Grit Biotechnology | 36 | 2027-05-01 | 2026-09-11 |
| Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia PID23 Injection - Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Zhujiang Hospital | 18 | 2026-08-01 | 2026-07-10 |
| CAR-T Cell Therapy for ALL CAR-T cell infusion - Relapsed Acute Lymphoblastic Leukemia (ALL) | Early Phase 1 | Recruiting | Dr. Zaineb Akram | 10 | 2026-06-01 | 2026-07-10 |
| Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia Momelotinib, Azacitidine - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes | Early Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 18 | 2026-03-19 | 2026-03-27 |
| Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL CD7 CAR-T cell intravenous infusion - T Lymphoblastic Lymphoma, T Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2026-03-15 | 2026-03-17 |
| Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib Pirtobrutinib - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Early Phase 1 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 30 | 2026-03-11 | 2026-11-12 |
| Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia SYNCAR-100 Injection - B-Cell Acute Lymphoblastic Leukemia | Early Phase 1 | Recruiting | Zhejiang University | 16 | 2026-02-28 | 2026-02-24 |
| IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma IASO104 - Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Leukemia (PCL) | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 40 | 2026-02-15 | 2026-01-20 |
| Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML CAR-T - AML (Acute Myeloid Leukemia), CAR-T | Early Phase 1 | Withdrawn | First Affiliated Hospital of Guangxi Medical University | 2026-01-05 | 2026-08-26 | |
| Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection - Acute Lymphoblastic Leukemia | Early Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2025-12-30 | 2026-04-27 |
| UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C) - Acute Myeloid Leukemia, Pediatric AML | Early Phase 1 | Recruiting | Baylor College of Medicine | 36 | 2025-10-22 | 2026-08-24 |
| Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL CD19 specific Chimeric Antigen Receptor T Cell - Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed | Early Phase 1 | Not yet recruiting | Nationwide Children's Hospital | 12 | 2025-10-01 | 2025-08-15 |
| CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia CD123+CLL-1 dual-target CAR-T cells sequential infusion CD7 CAR-T cells and bridging to allogeneic - AML - Acute Myeloid Leukemia | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2025-09-30 | 2025-10-01 |
| A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia GT801 Injection - B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL) | Early Phase 1 | Recruiting | Grit Biotechnology | 28 | 2025-09-26 | 2026-07-20 |
| Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies LV009 Injection Infusion - Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Adult | Early Phase 1 | Recruiting | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 19 | 2025-09-25 | 2025-12-31 |
| Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia CD117 CAR T-cells - Acute Myeloid Leukemia | Early Phase 1 | Recruiting | Zhejiang University | 50 | 2025-09-05 | 2025-08-27 |
| γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant Gamma-Delta T cell injection, Standard prophylactic treatment - Leukemia, Myeloid | Early Phase 1 | Withdrawn | Guangzhou Bio-gene Technology Co., Ltd | 2025-09-01 | 2026-05-28 | |
| A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia CAR-T cells Infusion chimeric antigen receptor T cells - Relapsed/Refractory Plasma Cell Leukemia, Relapsed/Refractory Multiple Myeloma | Early Phase 1 | Recruiting | The First Affiliated Hospital of Soochow University | 24 | 2025-07-23 | 2025-10-01 |
| The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT Ex-vivo expanded allogeneic γδ T cells - AML (Acute Myelogenous Leukemia), AML | Early Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2025-07-20 | 2025-08-17 |
| The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia VGO-Cs01p - T-ALL | Early Phase 1 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 9 | 2025-07-01 | 2025-05-15 |
Showing 20 of 129. Sign in to see all of them.
Leukemia, Myeloid, Acute (54) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (36) · Lymphoma, Non-Hodgkin (24) · Leukemia, Lymphocytic, Chronic, B-Cell (16) · Myelodysplastic Syndromes (15) · Multiple Myeloma (13) · Recurrence (11) · Lymphoma (10) · Lymphoma, B-Cell (9) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (9) · Burkitt Lymphoma (7) · Lymphoma, Mantle-Cell (7) · Hematologic Neoplasms (6) · Hodgkin Disease (6)
Hemic and Lymphatic Diseases (129) · Neoplasms by Histologic Type (129) · Hematologic Diseases (128) · Neoplasms (127) · Immune System Diseases (81) · Immunoproliferative Disorders (79) · Lymphoproliferative Disorders (78) · Lymphatic Diseases (72) · Leukemia, Lymphoid (58) · Leukemia, Myeloid (54) · Lymphoma (35) · Pathologic Processes (35) · Pathological Conditions, Signs and Symptoms (35) · Disease Attributes (33)
Cyclophosphamide (10) · Etoposide (5) · fludarabine (5) · Cytarabine (3) · Exercise (3) · Sirolimus (3) · Azacitidine (2) · Biopsy (2) · Cord Blood Stem Cell Transplantation (2) · Dexamethasone (2) · Doxorubicin (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Idarubicin (2) · Ifosfamide (2)
Zhejiang University (12) · Institute of Hematology & Blood Diseases Hospital, China (7) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (4) · iCell Gene Therapeutics (4) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (3) · He Huang (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Washington University School of Medicine (3) · Anhui Provincial Hospital (2) · Base Therapeutics (Shanghai) Co., Ltd. (2) · Baylor College of Medicine (2) · Case Comprehensive Cancer Center (2) · City of Hope Medical Center (2) · Grit Biotechnology (2) · Hrain Biotechnology Co., Ltd. (2)
China (64) · United States (50) · Germany (2) · Australia (1) · Czechia (1) · Denmark (1) · France (1) · Pakistan (1) · Sweden (1)
Fang Liu, MD, PhD (4) · He Huang, MD (4) · Hongyu Zhang, MD, PhD (4) · Kailin Xu, M.D., Ph.D. (2) · Margaret Kasner, MD (2) · Alexandra Stevens, MD (1) · Alexey V Danilov, MD (1) · Amanda Cashen, M.D. (1) · Bouthaina S Dabaja (1) · Brian Hill, MD (1) · Candido E. Rivera, M.D. (1) · Carlos Martin Sanchez, PhD (1) · Christian B Gocke, MD, PhD (1) · David Porter, MD (1) · Dehui Zou, Dr. (1)
PMID 32298202, PMID 32840736, PMID 33439382, PMID 34651291, PMID 35349631, PMID 35468680, PMID 35973200, PMID 36189306, PMID 36719647, PMID 36808074, PMID 37077913, PMID 37093350, PMID 37192741, PMID 38143760, PMID 38592213, PMID 40129522, PMID 40311885, PMID 40406106, PMID 40540129, PMID 40574863, PMID 40940923, PMID 41194247, PMID 41538301, PMID 41633358, PMID 41776652, PMID 42040934, PMID 42845554
P30CA033572 (2), P30CA043703 (2), 2017 (1), 2019 (1), P01CA068484 (1), P30CA006516 (1), P30CA015083 (1), P30CA072720 (1), R01CA277493 (1), R42CA257797 (1)